RENO, Nev., Oct. 9, 2025 — CIQ, Rocky Linux partner and high-performance software infrastructure company, today announced that FYR, a precision medicine tools company, has selected Fuzzball, CIQ’s computing platform, to power its analytics workflows.
FYR utilizes AI-enabled multiomic insights through its EV-Omics (EVO) platform to research disease mechanisms. By identifying RNA and protein biomarkers from EVs in blood, FYR’s mission is to uncover disease insights, build datasets to enhance clinical trials and deliver guidance for drug development.
The integration of CIQ’s Fuzzball is intended to amplify this capability by enabling the implementation of exploratory pipelines, allowing partners to interpret complex insights while maintaining the rigor and reliability of FYR’s platform. With Fuzzball, FYR can scale AI models from laptop prototypes to production-ready analytics environments.
“FYR is doing groundbreaking work in applying AI to life sciences, and Fuzzball is the engine that enables these tools to operate at scale,” said Bjorn Hovland, chief operating officer at CIQ. “This partnership is a powerful example of how CIQ’s technology accelerates innovation while ensuring the reproducibility required for regulated environments.”
Partnership Features:
- Scalable, Reliable Solutions: Pharma and biotech companies often struggle to scale proven models beyond small pilot projects. Fuzzball bridges that gap, transforming validated workflows into production-ready, automated pipelines without requiring significant new infrastructure or technical headcount.
- Reproducibility: Regulatory compliance relies on consistent, repeatable results. With Fuzzball, workflows can be preserved and rerun exactly as originally executed, providing the confidence needed for GLP, GXP, and FDA-regulated environments, without sacrificing speed or quality.
- Strategic Value: Pharma and biotech companies face increasing pressure to modernize analytics and future-proof operations. By working with FYR, pharma partners gain immediate access to advanced multiomic insights, while CIQ’s Fuzzball provides the scalable foundation to expand and sustain those capabilities.
Additional benefits include rapid onboarding, with CIQ environments deployable in an hour instead of a day, and a stored catalog that preserves custom workflows for easy reuse.
“Building a production-quality pipeline used to take weeks when factoring in training and scaling,” said Claire Seibold, director of software and data analytics at FYR. “CIQ’s Fuzzball gives us the ability to implement and scale these pipelines for 100x the throughput in a fraction of the time. It delivers results to our pharma partners at the speed and scale that today’s innovation-driven discovery market demands, while providing the scalability and reproducibility needed to bring AI-driven biomarker discovery into real-world clinical practice. Being part of the Two Bear Capital portfolio enables us to collaborate with like-minded companies like CIQ, fostering transformative innovation across the life sciences ecosystem.”
“The partnership between FYR and CIQ demonstrates the impact of strategic collaboration,” said Mark Adams, Ph.D., partner at Two Bear Capital. “By integrating CIQ’s Fuzzball into FYR’s EV-Omics platform, these two companies can deliver faster, high-quality insights that accelerate biomarker discovery and advance precision medicine, ultimately generating meaningful outcomes for patients.”
Together, FYR and CIQ are advancing the next generation of precision medicine by pairing innovative AI tools with a high-performance computing platform purpose-built for scale, efficiency and reproducibility.
